Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2020

View Archived Issues

Encouraging preliminary phase I data announced for VAC-2 in NSCLC

Mucolytic agent MUC-031 has beneficial effects in cystic fibrosis model

Boehringer and OBT expand collaboration to discover additional selective cancer targets

Copanlisib plus rituximab leads to significantly prolonged PFS in CHRONOS-3 study

Phase III ASTRAL-2 and ASTRAL-3 studies of guadecitabine do not meet primary endpoint

FDA transfers IND application OST-HER2 to OS Therapies

FDA clears IND to initiate phase Ib/IIa study of AP-PA02

Positive data from ILIAD study of peginterferon lambda in outpatients with COVID-19

Ono Pharmaceutical synthesizes bispecific antibodies targeting CD19 and PD-1

New Toll-like receptor 2 antagonists identified at Neuropore Therapies

University of Barcelona discovers soluble epoxide hydrolase and acetylcholinesterase inhibitors

New pantothenate kinase 3 inhibitors identified at St. Jude Children's Research Hospital

Genfleet Therapeutics patents RIP-1 inhibitors

Investigator-initiated study of IONIS-PKK-LRx in patients with COVID-19 begins

Phase II trial of GLPG-1972 in osteoarthritis does not meet primary objective

MRT-5500 elicits neutralizing antibodies against SARS-CoV-2 in vivo

Unite and conquer approach finds shared weaknesses of coronaviruses

Vorinostat + sirolimus or everolimus shows encouraging activity and safety in r/r Hodgkin's lymphoma

BP-C2 mitigates radiation-induced gastrointestinal syndrome in mice

The cross-talk of SNAI2 and Hippo pathway in breast cancer metastasis

Exonate cleared to begin phase Ib/II evaluation of EXN-407 for diabetic macular edema

FDA approves Keytruda for adults with relapsed or refractory classical Hodgkin's lymphoma

Chitinase-3-like protein 1 identified as cystic fibrosis therapeutic target

Arch begins phase II trial of LSALT to prevent COVID-19-related complications

ImmunityBio receives FDA clearance for phase I trial of hAd5-COVID-19

FDA accepts IND for phase I/II study of Nuvation's NUV-422 in high-grade gliomas